You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 3.1% | 4.0% |
| Div Cover | 3.2 | 2.6 |
| Op Mrgn | 21.9% | 28.5% |
| ROCE | 61.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | 10.0 | 0.0 |
| PEG | 0.4 | 2.1 |
| Price / Revenue | 2.0 | 2.0 |
| Price / Book value | 5.7 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 18.7% | -21.7% |
| PBT | 56.4% | n/a |
| EPS | 23.4% | 15.2% |
| DPS | -56.0% | 4.3% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | 30,821.00 | 4,800.00 | 119.40p | 15.6 | 2.3 | 7% | 80.00p | 4.3% |
| 2019-12-31 | 33,754.00 | 6,221.00 | 123.90p | 17.9 | 4.8 | 4% | 80.00p | 3.6% |
| 2020-12-31 | 34,099.00 | 6,968.00 | 115.90p | 14.5 | -2.2 | -6% | 80.00p | 4.8% |
| 2021-12-31 | 24,696.00 | 3,599.00 | 90.56p | 22.2 | -9.5 | -2% | 80.00p | 4.0% |
| 2022-12-31 | 29,324.00 | 5,628.00 | 139.70p | 10.3 | 0.4 | 23% | 44.00p | 3.1% |
| GSK disagrees with ranitidine evidence ruling in California Sharecast News | 24 Mar |
|---|---|
| Deutsche Bank upgrades GSK to 'buy' Sharecast News | 17 Mar |
| GSK upbeat on meningitis vaccine candidate, asthma treatment Sharecast News | 14 Mar |
| Statement: Zantac (ranitidine) litigation | 24-Mar-23 18:15 |
|---|---|
| Director/PDMR Shareholding | 21-Mar-23 23:58 |
| Director/PDMR Shareholding | 20-Mar-23 23:58 |
| Positive phase III results for MenABCWY vaccine | 14-Mar-23 15:28 |
| Nucala NDA accepted for review in China | 14-Mar-23 15:19 |